Shopping Cart
- Remove All
- Your shopping cart is currently empty
Vidofludimus hemicalcium (4sc-101; SC12267) is an orally active compound that acts as a dihydroorotate dehydrogenase (DHODH) inhibitor and serves as a novel modulator of the farnesoid X receptor (FXR). This immunomodulatory agent is utilized in the research of autoimmune disorders, including inflammatory bowel disease (IBD), and is explored for its potential in fatty liver disease research through FXR targeting.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,670 | 1-2 weeks | |
50 mg | $2,180 | 1-2 weeks | |
100 mg | $2,800 | 1-2 weeks |
Description | Vidofludimus hemicalcium (4sc-101; SC12267) is an orally active compound that acts as a dihydroorotate dehydrogenase (DHODH) inhibitor and serves as a novel modulator of the farnesoid X receptor (FXR). This immunomodulatory agent is utilized in the research of autoimmune disorders, including inflammatory bowel disease (IBD), and is explored for its potential in fatty liver disease research through FXR targeting. |
Alias | SC12267 hemicalcium, 4sc-101 hemicalcium ; SC12267 hemicalcium, 4sc-101 hemicalcium |
Molecular Weight | 375.4 |
Formula | C20H18FNO4.1/2Ca |
Cas No. | 1354012-90-0 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.